{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:24:01Z","timestamp":1788013441320,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijantimicag.2024.107328","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T13:22:38Z","timestamp":1725628958000},"page":"107328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetic and preclinical safety studies of endolysin-based therapeutic for intravenous administration"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-8056","authenticated-orcid":false,"given":"Nataliia P.","family":"Antonova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria V.","family":"Vasina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6946-2156","authenticated-orcid":false,"given":"Igor V.","family":"Grigoriev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksei I.","family":"Laishevtsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey V.","family":"Kapustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1891-0005","authenticated-orcid":false,"given":"Vasiliy A.","family":"Savinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-2464","authenticated-orcid":false,"given":"Aleksei M.","family":"Vorobev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei V.","family":"Aleshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia A.","family":"Zackharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timofey A.","family":"Remizov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine V.","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey M.","family":"Yudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir A.","family":"Gushchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107328_bib0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","article-title":"The global preclinical antibacterial pipeline","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics10020124","article-title":"Phage-encoded endolysins","volume":"10","author":"Abdelrahman","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.copbio.2020.09.012","article-title":"Bacteriophage endolysins - extending their application to tissues and the bloodstream","volume":"68","author":"Schmelcher","year":"2021","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/1040841X.2020.1809346","article-title":"Advanced engineering of third-generation lysins and formulation strategies for clinical applications","volume":"46","author":"De Maesschalck","year":"2020","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/v13040680","article-title":"The advantages and challenges of using endolysins in a clinical setting","volume":"13","author":"Murray","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10121497","article-title":"Treating bacterial infections with bacteriophage-based enzybiotics: in vitro, in vivo and clinical application","volume":"10","author":"Danis-Wlodarczyk","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030440","article-title":"Modulation of endolysin LysECD7 bactericidal activity by different peptide tag fusion","volume":"10","author":"Antonova","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-024-01065-y","article-title":"Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections","volume":"31","author":"Vasina","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0009","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1134\/S0003683822100027","article-title":"Engineered endolysin LysECD7-SMAP reveals antimicrobial synergy with antibiotics and restores sensitivity in gram-negative pathogens","volume":"58","author":"Arshinov","year":"2022","journal-title":"Appl Biochem Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis","volume":"929","author":"Gabrielsson","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0011","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0012","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4049\/jimmunol.85.5.469","article-title":"Anaphylactogenic properties of soluble antigen-antibody complexes in the guinea pig and rabbit","volume":"85","author":"Weigle","year":"1960","journal-title":"J Immunol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-4939-8549-4_7","article-title":"Methylated bovine serum albumin (mBSA)-induced delayed-type hypersensitivity in mice","volume":"1803","author":"Sido","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0014","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/19420862.2015.1115937","article-title":"Key factors influencing ADME properties of therapeutic proteins: a need for ADME characterization in drug discovery and development","volume":"8","author":"Tibbitts","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0015","doi-asserted-by":"crossref","first-page":"F115","DOI":"10.1152\/ajprenal.00377.2019","article-title":"A noninvasive method to study the evolution of extracellular fluid volume in mice using time-domain nuclear magnetic resonance","volume":"319","author":"Morla","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/138920009789895499","article-title":"Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies","volume":"10","author":"Lin","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0017","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s11095-017-2219-y","article-title":"Influence of molecular size on the clearance of antibody fragments","volume":"34","author":"Li","year":"2017","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0018","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/1440-1681.12613","article-title":"Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period","volume":"43","author":"Jun","year":"2016","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02629-16","article-title":"Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers","volume":"61","author":"Jun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0020","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1128\/AAC.02232-13","article-title":"Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient","volume":"58","author":"Jun","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.841905","article-title":"Direct lytic agents: novel, rapidly acting potential antimicrobial treatment modalities for systemic use in the era of rising antibiotic resistance","volume":"13","author":"Schuch","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/v10110638","article-title":"Safety studies of pneumococcal endolysins Cpl-1 and Pal","volume":"10","author":"Harhala","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11070966","article-title":"Immunogenicity of endolysin PlyC","volume":"11","author":"Harhala","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.748718","article-title":"Discovering the potentials of four phage endolysins to combat gram-negative infections","volume":"12","author":"Vasina","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2680160","article-title":"Fundamentals and methods for T- and B-cell epitope prediction","volume":"2017","author":"Sanchez-Trincado","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0026","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","article-title":"Immunogenicity of therapeutic proteins: clinical implications and future prospects","volume":"24","author":"Schellekens","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2024.107328_bib0027","first-page":"314","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self\/Nonself-Immune Recognition Signal"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T15:54:47Z","timestamp":1730735687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0924857924002449"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107328","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and preclinical safety studies of endolysin-based therapeutic for intravenous administration","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107328"}}